Market Overview

UPDATE: Piper Jaffray Reduces PT to $92 on Monsanto on Pipeline Valuation

Share:
Related MON
Benzinga's M&A Chatter for Tuesday July 19, 2016
Monsanto Terms Bayer's Revised Proposal As Inadequate And Insufficient
Retirement Strategy: 5 Pharmaceutical Dividends To Buy Here (Seeking Alpha)

Piper Jaffray reiterates its Overweight rating on Monsanto (NYSE: MON) but reduces its price target on shares from $97 to $92 on compassed valuation multiples.

Piper Jaffray comments, "As valuation multiples have compressed in the agriculture sector (as well as large cap biotech – a commonly used peer group for MON shares), scrutiny around the sustainability of MON's premium multiple has intensified. In this note, we revisit our Overweight thesis on MON shares and outline how Monsanto is positioned to deliver at least mid-teens annual earnings growth over the next 3 years, which should be supportive of sustained P/E valuations. Latin America will continue to be a key profit growth driver over the next 2 years - a factor that we believe investors under-estimate. Following a review of Monsanto's R&D pipeline, we provide a framework to value this pipeline – which we believe is worth approximately $13 per share."

MON closed at $71.30 on Tuesday.

Latest Ratings for MON

DateFirmActionFromTo
Jul 2016CitigroupMaintainsNeutral
Jun 2016UBSMaintainsBuy
May 2016Atlantic EquitiesDowngradesOverweightNeutral

View More Analyst Ratings for MON
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (MON)

View Comments and Join the Discussion!